Lund, Sweden, October 20, 2021 – Alligator Bioscience AB (“Alligator” or the “Company”) today announced that the Company was notified that the first patient has been dosed in its Phase II clinical trial collaboration with Shanghai Henlius Biotech, Inc. and AbClon, Inc. Alligator out-licensed AC101 to AbClon, Inc. in October 2016. Abclon, Inc. subsequently sub-licensed AC101 in China for clinical development by Shanghai Henlius Biotech Inc. (November 7, 2018 press release).
“We are happy to see that Henlius Biotech has dosed the first patient dosed with AC101 (HLX22). Previously, the phase I clinical trial demonstrated that HLX22 is well tolerated and has good safety profiles. Phase II will reinforce safety and compare the clinical efficacy in AC101 (HLX22) and placebo group,” said Søren Bregenholt, CEO of Alligator Bioscience. “The commencement of dosing in the Phase II study with AC101 (HLX22) is an important step forward for our best-in-class antibodies technologies and partner collaborations.”
For further information, please contact:
Julie Silber, Investor Relations
Phone: +46 46-540 82 23
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. The pipeline includes two clinical assets: mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Alligator Bioscience is co-developing ALG.APV-527 with Aptevo Therapeutics Inc. and an undisclosed molecule based on its proprietary Neo-X-Prime™ technology platform with MacroGenics Inc. Out-licensed programs include AC101 in clinical development by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX). Alligator is headquartered in Lund, Sweden. For more information, please visit http://www.alligatorbioscience.com.
About Shanghai Henlius Biotech, Inc.
Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 3 products have been launched in China, 1 in the European Union (EU), the New Drug Applications (NDA) of 3 products accepted for review in China. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing, and commercialization. It has established global R&D centers and a Shanghai-based manufacturing facility certificated by China and the EU Good Manufacturing Practice (GMP).
About AbClon Inc.
AbClon, based in Seoul, South Korea, has been dedicated to the research, development of new antibody drugs. The company has established two platforms, Novel Epitope Screening Technology (NEST) and monoclonal antibody platform (AffiMab), to accelerate the discovery and development of innovative antibody therapeutics.